Greasy hair proves to be an unexpected possibility for obesity treatment 30 July 2021 | By Anna Begley (Drug Target Review) Researchers have revealed that the immune system of obese mice treated with TSLP released lipids through sebaceous glands.
Removal of RNA-binding protein improves leukaemia survival 30 July 2021 | By Anna Begley (Drug Target Review) Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
Novel insulin-producing implant to be created for type 1 diabetics 30 July 2021 | By Anna Begley (Drug Target Review) JDRF funds development of an insulin-producing implant to regulate blood glucose levels in type 1 diabetes patients.
Farnesol shows potential to prevent and treat Parkinson’s disease 29 July 2021 | By Anna Begley (Drug Target Review) Researchers have added to evidence that farnesol prevents and reverses brain damage linked to Parkinson’s disease in mouse models.
AKT degrader may become a new, effective treatment for many cancers 29 July 2021 | By Anna Begley (Drug Target Review) Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.
Genetic treatment reverses age-related memory loss in mice 28 July 2021 | By Anna Begley (Drug Target Review) Scientists have shown that manipulating the perineuronal nets (PNNs) in the brains of mice led to the reversal of age-related memory loss.
“Untreatable” cases of cystic fibrosis may be undermined by new therapy 28 July 2021 | By Anna Begley (Drug Target Review) An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
Exosome formulation developed for choroidal neovascularisation therapy 27 July 2021 | By Anna Begley (Drug Target Review) An exosome formulation has been created to deliver vascular endothelial-growth factor (VEGF) antibodies for choroidal neovascularisation therapy in models.
Inhibiting PIP4K enzymes could help immune system fight cancer 27 July 2021 | By Anna Begley (Drug Target Review) Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
Llama nanobodies could serve as new treatment for HCMV 26 July 2021 | By Anna Begley (Drug Target Review) Scientists have developed a “llama nanobody” that is capable of chasing out human cytomegalovirus (HCMV) so it is detected by the immune system.
New “atlas” charts how antibodies attack COVID-19 Spike variants 26 July 2021 | By Anna Begley (Drug Target Review) A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
Personalised organoid models may improve immunotherapy treatment 23 July 2021 | By Anna Begley (Drug Target Review) Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
Algorithm helps find best drug targets for all COVID-19 variants 23 July 2021 | By Anna Begley (Drug Target Review) A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.
Bacterial metabolites could increase tumour therapy efficiency 22 July 2021 | By Anna Begley (Drug Target Review) Bacterial metabolites showed an increase in the cytotoxic activity in immune cells that could potentially influence efficiency of tumour therapies.
Researchers develop toxicity test for placenta and embryos 22 July 2021 | By Anna Begley (Drug Target Review) A Swiss team have created a laboratory test that incorporates the placenta into embryotoxicity assessments without damaging foetuses.
